Cubist Pharmaceuticals has appointed Alison Lawton to its board of directors.

With the addition of Lawton, the board of directors will increase to 10 members, nine of whom are independent.

Lawton currently serves as senior vice president, general manager Biosurgery at Genzyme.

She joined Genzyme in 1991 as an international regulatory affairs specialist. As head of Genzyme Biosurgery, she is responsible for the company's global orthopedics, biosurgical specialty, and cell therapy and regenerative medicine businesses. Prior to this position, she oversaw global market access.

Before joining Genzyme, Lawton worked at Parke-Davis in the United Kingdom.